Skip to main content
. Author manuscript; available in PMC: 2017 Feb 3.
Published in final edited form as: J Registry Manag. 2016 Fall;41(3):134–142.

Table 3.

Tyrosine Kinase Inhibitor use by BCR_ABL Test result

a: State A included
Receipt of TKIs (N=685)
BCR_ABL Testing TKI given No TKI given Total
Tested (360 positive) 296 (43.2%) 78 (11.4%) 374 (54.9%)
Not Tested or Unknown 73 (10.7%) 238 (34.7%) 311 (45.4%)
Total 369 (53.9%) 316 (6.7%) 685
b: State A removed
Receipt of TKIs (n=393)
BCR_ABL Testing TKI given No TKI given Total
Tested (360 positive) 267 (67.9%) 41 (10.4%) 308 (78.4%)
Not Tested or Unknown 38 (9.7%) 47 (12.0%) 85 (21.6%)
Total 305 (77.6%) 88 (22.4%) 393